Don’t miss this just because it’s rare: Unmasking a hidden threat for optimal ALL treatment in young adults
Key Takeaways
Industry Buzz
“Asparaginase allergy can be silent—a ‘silent hypersensitivity’—without clinical symptoms, but it can inactivate the drug and make it ineffective.” — Ibrahim T. Aldoss, MD, board-certified oncologist, hematologist, and internist at City of Hope, Orange County, CA
“While many patients have clinically apparent allergic reactions to asparaginase, some patients’ reactions are subtle [and] can overlap with infusion reactions and associated symptoms from asparaginase-induced increases in blood ammonia levels.” — Seth Karol, MD, pediatric oncologist at St. Jude Children's Research Hospital
In 2024 alone, more than 6,100 new cases of acute lymphoblastic leukemia (ALL) were diagnosed in the US. And the disease strikes hardest in the youngest—ALL makes up nearly 25% of all childhood cancers.[][]
Asparaginase (ASNase) remains a cornerstone of chemo regimens for ALL, especially in adolescents and young adults (AYAs).
But there’s a quiet threat that’s often missed: hypersensitivity reactions to E. coli ASNase, particularly its pegylated form, PEG-ASNase. These allergic reactions are a surprisingly common reason patients stop or don’t get optimal dosing.[]
Why allergies fly under the radar
Allergic reactions to ASNase tend to get the spotlight in pediatric protocols. But that’s led to an outdated assumption: that older patients aren’t at as much risk. Recent data says otherwise.
According to a recent consensus paper from an expert panel, hypersensitivity reactions occur in about 10%–30% of patients on native E. coli ASNase and 3%–24% on PEG-ASNase. Those with prior exposure face even higher risk when re-treated.[]
In real-world AYA data, PEG-ASNase reactions were seen in 7.7%[] of patients, which is more than double the 3.3%[] rate in kids. The reactions range from mild cutaneous eruptions to severe anaphylaxis—often subtle and easy to misattribute to routine chemo side effects.
Seth Karol, MD, co-author of the expert consensus paper and a pediatric oncologist at St. Jude Children's Research Hospital, tells MDLinx, “While many patients have clinically apparent allergic reactions to asparaginase, some patients’ reactions are subtle... The symptoms of reaction, including flushing and vomiting, can overlap with infusion reactions and associated symptoms from asparaginase-induced increases in blood ammonia levels.”
Ibrahim T. Aldoss, MD, board-certified medical oncologist, hematologist, and internist from City of Hope in Orange County, CA, says, “Symptoms such as fever, rash, hypotension, or GI discomfort may be confused with chemotherapy side effects, cytokine release, infection, or even tumor lysis syndrome. Furthermore, asparaginase allergy can be silent— a ‘silent hypersensitivity’—without clinical symptoms, but it can inactivate the drug and make it ineffective.”
The stakes are high. Missed or delayed diagnosis can lead to worse allergic responses down the line—and worse outcomes.[][]
Clinical consequences
Failing to catch ASNase allergy early can compromise induction therapy and increase relapse risk. In the CALGB 10403 study of young adults (17–39) with ALL, nearly one-third had to discontinue PEG-ASNase early. The result? Lower survival rates—especially in standard-risk patients.[]
Dr. Aldoss, who was the lead researcher on the study, tells MDLinx, “Reduced cumulative exposure to asparaginase, due to treatment toxicity, silent hypersensitivity, or non-compliance, has been associated with inferior event-free survival and overall survival in acute lymphoblastic leukemia patients. Failure to recognize and appropriately manage E. coli asparaginase allergy can compromise remission induction treatment outcomes and increase relapse risk.”
How to recognize and diagnose
Researchers at St. Jude’s Children’s Research Hospital have mapped the common signs of PEG-ASNase hypersensitivity reactions.[]
The reactions usually happen fast—typically within 60 minutes of infusion, and often within the first 10. Mild to moderate reactions may present as transient flushing, rash, urticaria, or low-grade fever. More severe grade 3 reactions, which accounted for over 70% of documented cases, typically involve bronchospasm, hypotension, angioedema, or a constellation of allergy-related symptoms that necessitate immediate pharmacologic intervention. Anaphylaxis, while rare, is still possible. Common symptoms include dyspnea, pruritus, vomiting, cough, and edema, either localized or generalized.
Interestingly, most reactions occur after the second or third dose, especially when doses are spaced out during treatment phases. That gap may trigger immune reactivation, upping the risk.
After the diagnosis
If you suspect an allergic reaction, it’s important to act fast. Patients experiencing significant reactions should be promptly treated with supportive care and may require discontinuation of PEG-ASNase. In these cases, an alternative formulation, such as Erwinia asparaginase, should be substituted without delay to maintain the antileukemic effect of asparagine depletion and avoid treatment setbacks.[]
Read Next: Challenging, but not impossible: Oncologists share their best practices for predicting E. coli asparaginase allergies